Journal article
Precision Medicine in Myeloid Malignancies: Hype or Hope?
Current hematologic malignancy reports, Vol.17(6), pp.217-227
12/01/2022
DOI: 10.1007/s11899-022-00674-4
PMID: 35972641
Abstract
Purpose of Review We review how understanding the fitness and comorbidity burden of patients, and molecular landscape of underlying acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) at the time of diagnosis is now integral to treatment.
Recent Findings The upfront identification of patients' fitness and molecular profile facilitates selection of targeted and novel agents, enables risk stratification, allows consideration of allogeneic hematopoietic cell transplantation in high-risk patients, and provides treatment selection for older (age >= 75) or otherwise unfit patients who may not tolerate conventional treatment. The use of measurable residual disease (MRD) assessment improves outcome prediction and can also guide therapeutic strategies such as chemotherapy maintenance and transplant. In recent years, several novel drugs have received FDA approval for treating patients with AML with or without specific mutations. A doublet and triplet combination of molecular targeted and other novel treatments have resulted in high response rates in early trials. Following the initial success in AML, novel drugs are undergoing clinical trials in MDS.
Summary Unprecedented advances have been made in precision medicine approaches in AML and MDS. However, lack of durable responses and long-term disease control in many patients still present significant challenges, which can only be met, to some extent, with innovative combination strategies throughout the course of treatment from induction to consolidation and maintenance.
Details
- Title: Subtitle
- Precision Medicine in Myeloid Malignancies: Hype or Hope?
- Creators
- Shristi Upadhyay Banskota - University of Nebraska Medical CenterNabin Khanal - Franciscan University of SteubenvilleRosalyn Marar - University of Nebraska Medical CenterPrajwal Dhakal - University of IowaVijaya Raj Bhatt - University of Nebraska Medical Center
- Resource Type
- Journal article
- Publication Details
- Current hematologic malignancy reports, Vol.17(6), pp.217-227
- Publisher
- Current Medicine Group
- DOI
- 10.1007/s11899-022-00674-4
- PMID
- 35972641
- ISSN
- 1558-8211
- eISSN
- 1558-822X
- Number of pages
- 11
- Language
- English
- Date published
- 12/01/2022
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984360047302771
Metrics
13 Record Views